Scholarlink

Purpose <p>The Kirsten rat sarcoma viral oncogene (<i>KRAS</i>) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of <i>KRAS</i> across various cancer types.</p> Methods <p>Using next-generation sequencing (NGS) technology and a panel of 520 genes, <i>KRAS</i> mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.</p> Results <p>An analysis of 10,820 tumor samples found <i>KRAS</i> mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence of <i>KRAS</i> mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24%. <i>KRAS</i> G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while <i>KRAS</i> G12V mutation is predominant in uterine cancer, and <i>KRAS</i> G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and <i>KRAS</i> G13D/G12V mutations in colorectal cancer. <i>KRAS</i> G13D notably affected TMB in uterus cancer, while <i>KRAS</i> G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between <i>KRAS</i> G13D/G12V mutations and MSI-H in colorectal cancer.</p> Conclusions <p><i>KRAS</i> mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific <i>KRAS</i> mutations are associated with TMB and MSI in various cancer types.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pan-cancer analysis to character the clinicopathological and genomic features of KRAS-mutated patients in China

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月27日

查看全文
  • Liyuan Wu,
  • Wei Rao,
  • Lei Guo,
  • Fanshuang Zhang,
  • Weihua Li,
  • Jianming Ying

摘要

Purpose

The Kirsten rat sarcoma viral oncogene (KRAS) is the most frequently mutated oncogene in human cancers. Significant advancements have been made in targeted therapy and immunotherapy for this gene in recent years, underscoring the importance of comprehensively understanding the genomic landscape of KRAS across various cancer types.

Methods

Using next-generation sequencing (NGS) technology and a panel of 520 genes, KRAS mutations, tumor mutation burden (TMB), and microsatellite instability (MSI-H) status were investigated.

Results

An analysis of 10,820 tumor samples found KRAS mutations in 19.97% of cases. Pancreatic cancer showed the highest prevalence of KRAS mutations at 73.51%, while colorectal at 41.45%, uterine at 21.23%, and lung cancer at 11.24%. KRAS G12D mutation is most common in pancreatic, colorectal, and gastric cancers, while KRAS G12V mutation is predominant in uterine cancer, and KRAS G12C mutation is most frequent in lung cancer. Significant correlations were found between TMB and KRAS G13D/G12V mutations in colorectal cancer. KRAS G13D notably affected TMB in uterus cancer, while KRAS G12C mutation was linked to high TMB in lung cancer. Moreover, statistical analysis revealed a significant association between KRAS G13D/G12V mutations and MSI-H in colorectal cancer.

Conclusions

KRAS mutations were most frequent in cancers of the digestive, female reproductive, and respiratory systems. Specific KRAS mutations are associated with TMB and MSI in various cancer types.